Satellos Bioscience (MSLE) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed Organigram Global (OGI) over the past year, losing 5.9% versus a loss of 49.1%. Over five years, MSLE leads with a -53.9% price change compared with -90.1% for OGI. Satellos Bioscience is the larger company by market cap ($137.1 million vs $133.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MSLE | OGI |
|---|---|---|
| Share price | $6.46 | $0.9267 |
| Market cap | $137.06M | $133.59M |
| 1-day change | -5.56% | -0.53% |
| YTD return | +9.86% | -44.84% |
| 1-year return | -5.89% | -49.08% |
| 5-year return | -53.95% | -90.10% |
| P/E ratio (TTM) | — | 2.16 |
| Forward P/E | — | 38.61 |
| EPS (TTM) | $-1.95 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-24.87M | — |
| 52-week high | $13.40 | $2.24 |
| 52-week low | $5.30 | $0.853 |
| Distance from 52-week high | -51.77% | -58.63% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +274.15% | — |
| Average volume | 46.92K | 855.47K |
| Shares outstanding | 21.22M | 144.15M |
| Employees | 18 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed OGI by 43.2 percentage points over the past year.
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
MSLE vs OGI FAQ
Which is bigger, Satellos Bioscience or Organigram Global?
Satellos Bioscience (MSLE) is larger, with a market capitalization of $137.06M compared with $133.59M for Organigram Global (OGI).
Which stock has performed better over the past year, MSLE or OGI?
MSLE returned -5.89% over the past 12 months, compared with -49.08% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are Satellos Bioscience and Organigram Global in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.